Advertisement

Topics

Search Results for "Sjogren A Belimumab"

03:08 EDT 18th August 2017 | BioPortfolio

Matching Channels

None

Matching News

GSK invests $139m to increase Benlysta (belimumab) production capacity

GSK is investing $139m in its biopharmaceutical manufacturing site located in Rockville, Maryland, to expand the production of Benlysta (belimumab).

US of Salivary Glands May Have Role in Diagnosing Sjogren's

Ultrasonography of the major salivary glands may have a role in the diagnostic evaluation of patients with clinically suspected primary Sjogren's syndrome, researchers from the Netherlands report. R...

Sjogren's Syndrome Market Insights, Epidemiology and Market Forecast2023 [Updated: 30052017] Prices from USD $4208

DelveInsight's Sjogren's Syndrome Market Insights, Epidemiology and Market Forecast2023 Reports provides an overview of the disease and global market trends of the Sjogren's Syndrome for the seven ma...

Ectopic germinal center and megalin defect in primary Sjogren syndrome with renal Fanconi syndrome

This study reports the clinical and pathological features of 12 cases of primary Sjogren syndrome (pSS) with renal involvement presenting with proximal tubular dysfunction in a single center, and inve...

Belimumab plus standard lupus therapy seen as safe, effective over 10 years

MADRID — Belimumab plus standard therapy was safe and effective over 10 years in patients with lupus, according to findings presented at the EULAR Annual Congress. “In lupus, the underlying diseas...

Gilead: Don't Buy It Based On Sjogren's Syndrome

FDA Clears Self-injectable Belimumab (Benlysta) for SLE

FDA Approvals

Self-Injectable Benlysta Approved in Lupus

(MedPage Today) -- Subcutaneous belimumab OK'd based on placebo-controlled trial

Matching PubMed Articles

Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study.

Objective To assess the efficacy and safety of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). Methods Patients with moderate-to-severe SLE (SELENA-SLEDAI ≥8) were r...

A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.

Objective Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimu...

Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.

Both BLISS-52 and BLISS-76 international phase III trials in Systemic Lupus Erythematosus (SLE) met their primary outcomes; however, they were not designed to assess the efficacy of belimumab for the ...

Impact of Sjogren's syndrome on Parkinson's disease: A nationwide case-control study.

To investigate whether Sjogren's syndrome would have an influence on the development of Parkinson's disease.

Belimumab for the treatment of recalcitrant cutaneous lupus.

Background Belimumab is a monoclonal antibody that reduces B lymphocyte survival by blocking the binding of soluble human B lymphocyte stimulator (BLyS) to its B cell receptors. The utility of belimum...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement